Krystal Biotech (KRYS) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Krystal Biotech (KRYS) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 77.3% versus a gain of 4.7%. Over five years, KRYS leads with a +566.2% price change compared with +37.2% for NBIX. Neurocrine Biosciences is the larger company by market cap ($14.58 billion vs $9.61 billion), about 1.5 times the size, while Krystal Biotech is growing revenue faster (+33.9% vs +21.4%).
On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.1x vs 34.8x for Krystal Biotech). Krystal Biotech converts more of its revenue into profit, with a net margin of 52.6% versus 16.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRYS | NBIX |
|---|---|---|
| Share price | $324.57 | $143.47 |
| Market cap | $9.61B | $14.58B |
| 1-day change | -0.69% | -1.40% |
| YTD return | +31.65% | +1.16% |
| 1-year return | +77.34% | +4.72% |
| 5-year return | +566.19% | +37.24% |
| P/E ratio (TTM) | 40.67 | 21.04 |
| Forward P/E | 34.83 | 12.08 |
| EPS (TTM) | $7.98 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $389.13M | $2.86B |
| Revenue growth (YoY) | +33.94% | +21.45% |
| Net income (latest FY) | $204.83M | $478.60M |
| Gross margin | — | 98.18% |
| Operating margin | 41.45% | 21.64% |
| Net margin | 52.64% | 16.73% |
| 52-week high | $382.54 | $186.12 |
| 52-week low | $179.19 | $122.14 |
| Distance from 52-week high | -15.15% | -22.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +20.81% | +44.48% |
| Average volume | 381.19K | 1.30M |
| Shares outstanding | 29.60M | 101.65M |
| Employees | 295 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRYS has outperformed NBIX by 72.6 percentage points over the past year.
- Krystal Biotech trades at a higher earnings multiple (40.7x vs 21.0x trailing P/E).
- Krystal Biotech is more profitable, keeping 52.6 cents of every revenue dollar as net income versus 16.7 cents for Neurocrine Biosciences.
- Krystal Biotech grew revenue faster in its latest fiscal year (+33.94% vs +21.45%).
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
KRYS vs NBIX FAQ
Which is bigger, Krystal Biotech or Neurocrine Biosciences?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.58B compared with $9.61B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, KRYS or NBIX?
KRYS returned +77.34% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KRYS or NBIX?
NBIX has the lower trailing P/E at 21.0, versus 40.7 for KRYS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Krystal Biotech and Neurocrine Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.